Aspergillus isolation in nontuberculous mycobacterial pulmonary disease: Associated with antimycobacterial treatment initiation but not response

被引:3
作者
Raats, Daan [1 ,2 ,3 ]
Aldhaheri, Sharina M. S. [4 ]
Marras, Theodore K. [1 ,3 ]
Mehrabi, Mahtab [1 ]
Brode, Sarah K. [1 ,2 ,3 ]
机构
[1] Univ Hlth Network, Toronto Western Hosp, Dept Med, Div Respirol, 399 Bathurst St, Toronto, ON M5T 2S8, Canada
[2] West Pk Healthcare Ctr, Dept Resp Med, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Respirol, Toronto, ON, Canada
[4] Tawam Hosp, Pulm Dept, Internal Med, Al Ain, U Arab Emirates
关键词
Aspergillus; Nontuberculous mycobacterial pulmonary; disease; Culture conversion; Radiologic evolution; AVIUM COMPLEX; CLINICAL-SIGNIFICANCE; INFECTION; DIAGNOSIS; OUTCOMES; RISK;
D O I
10.1016/j.rmed.2021.106338
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Chronic pulmonary aspergillosis is a serious complication of nontuberculous mycobacterial pulmonary disease (NTM-PD), and diagnosis remains challenging. The present study examined associations between the respiratory isolation of Aspergillus and the clinical characteristics and treatment outcomes of patients with NTMPD. Methods: All patients meeting NTM-PD criteria as defined by the ATS/IDSA statement, with at least one respiratory sample cultured for fungi, were included in this retrospective cohort analysis. Patients with at least one respiratory sample isolating Aspergillus were compared to patients who did not isolate Aspergillus. The primary outcomes were culture conversion and radiologic evolution 12 months after NTM-PD treatment initiation. Results: During a 12 year period, 497 patients meeting the inclusion criteria were seen in our tertiary care center, of whom 130 grew Aspergillus. Median follow up after NTM-PD diagnosis was 46 months. Inhaled corticosteroid use, a nodular-bronchiectatic CT pattern and NTM-PD treatment initiation were more frequent in patients who isolated Aspergillus compared to those who did not (p-value respectively 0.01, 0.03 and < 0.001). Rates of culture conversion (63.0% vs. 62.2%, respectively; p-value 1) and radiologic evolution (improvement or stability in 69.7% vs. 77.2%, respectively; p-value 0.25) were not significantly different between treatment groups. Likewise, culture reversion rate and 5-year mortality were not significantly different. Additionally, A. fumigatus and repeated detection of Aspergillus were not associated with treatment outcomes. Conclusion: There was no association between respiratory isolation of Aspergillus and NTM-PD treatment outcomes in this cohort. However, treatment for NTM-PD was initiated more frequently in patients who isolated Aspergillus.
引用
收藏
页数:7
相关论文
共 50 条
[31]   BACES Score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease [J].
Kim, Hyung-Jun ;
Kwak, Nakwon ;
Hong, Hyunsook ;
Kang, Noeul ;
Im, Yunjoo ;
Jhun, Byung Woo ;
Yim, Jae-Joon .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (02) :230-236
[32]   Nonpharmacological treatment for patients with nontuberculous mycobacterial lung disease [J].
Lan, Chou-Chin ;
Lai, Sheng-Ru ;
Chien, Jung-Yien .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 :S42-S50
[33]   Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis [J].
Kunst, H. ;
Wickremasinghe, M. ;
Wells, A. ;
Wilson, R. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (02) :352-357
[34]   Impact of bacterial co-isolation on treatment initiation and long-term prognosis of patients with nontuberculous mycobacterial pulmonary disease: analysis of a prospective cohort study [J].
Kim, Joong-Yub ;
Kim, Sung A. ;
Hyung, Kwonhyung ;
Yim, Jae-Joon ;
Kwak, Nakwon .
BMC INFECTIOUS DISEASES, 2024, 24 (01)
[35]   Isolation of nontuberculous mycobacteria and Nocardia via mycobacterial culture from pulmonary specimens [J].
Sun, Hongli ;
Liu, Wenjing ;
Liu, Lingli ;
Sun, Xuefeng .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2025, 111 (04)
[36]   Clofazimine serum concentration and safety/efficacy in nontuberculous mycobacterial pulmonary disease treatment [J].
Watanabe, Fumiya ;
Fujiwara, Keiji ;
Furuuchi, Koji ;
Ito, Masashi ;
Hanada, Kazuhiko ;
Kodama, Tatsuya ;
Aono, Akio ;
Mitarai, Satoshi ;
Yoshiyama, Takashi ;
Kurashima, Atsuyuki ;
Ohta, Ken ;
Morimoto, Kozo .
RESPIRATORY MEDICINE, 2024, 231
[37]   Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998-2010 [J].
Marras, Theodore K. ;
Mendelson, David ;
Marchand-Austin, Alex ;
May, Kevin ;
Jamieson, Frances B. .
EMERGING INFECTIOUS DISEASES, 2013, 19 (11) :1889-1891
[38]   Who should be treated for nontuberculous mycobacterial pulmonary disease? [J].
Ito, Yutaka .
RESPIRATORY INVESTIGATION, 2023, 61 (04) :387-388
[39]   Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review [J].
Prevots, D. Rebecca ;
Marshall, Julia E. ;
Wagner, Dirk ;
Morimoto, Kozo .
CLINICS IN CHEST MEDICINE, 2023, 44 (04) :675-721
[40]   Nontuberculous Mycobacterial Pulmonary Disease: Clinical Epidemiologic Features, Risk Factors, and Diagnosis The Nontuberculous Mycobacterial Series [J].
Kumar, Kartik ;
Loebinger, Michael R. .
CHEST, 2022, 161 (03) :637-646